Literature DB >> 16379157

[A preliminary study of the administration of carbapenem antibiotics in sepsis patients on the basis of the administration time].

Masahiro Kojika1, Nobuhiro Sato, Masanori Hakozaki, Yasusi Suzuki, Gaku Takahasi, Sigeatu Endo, Kenji Suzuki, Go Wakabayasi.   

Abstract

UNLABELLED: It is important to take into consideration the duration for which the plasma concentration of the drug is higher than the Minimal Inhibitory Concentration during treatment with carbapenem antibiotics, because the antibiotics are time-dependent drugs. A preliminary study of the administration of carbapenem antibiotics on the basis of the pharmacokinetics/pharmacodynamics (PK/PD) was conducted.
SUBJECTS: Ten patients with intraabdominal infection.
METHODS: The patients were divided into two groups: the first group was assigned to administration of a carbapenem antibiotic (meropenem) at a daily dose of 0.5 g in 3 divided doses, each dose by intravenous infusion over 3 hours (Group 3 H), and the other group was assigned to administration of each dose over 30 minutes (Group 30 M). The body temperature (BT), white blood cell count (WBC), serum C-reactive protein (CRP) level, and the systemic inflammatory reactive syndrome (SIRS) score before and 96 hours after the drug administration were compared between Group 3 H and Group 30 M.
RESULTS: There were 5 patients (mean age, 67.4+/-14.6 years) in Group 3H and 5 patients (mean age, 60.0+/-12.8 years) in Group 30 M. The evaluated parameters (BT, WBC, CRP, SIRS score) before the drug administration in Groups 3 H and 30M were not significant. Group 3 H showed significant decreases in the SIRS scores at 96 hours after the drug administration, however, there were no significant differences in the BT, WBC or CRP between the two groups. DISCUSSION: Group 3 H showed early improvement in the SIRS scores. Administration of carbapenem antibiotics based on the PK/PD is important, and requires further studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16379157

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  7 in total

1.  Should IV Antibiotics Be Administered by Prolonged Infusion?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2010-05

Review 2.  Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Authors:  Jennifer Shiu; Erica Wang; Aaron M Tejani; Michael Wasdell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

3.  Continuous beta-lactam infusion in critically ill patients: the clinical evidence.

Authors:  Mohd H Abdul-Aziz; Joel M Dulhunty; Rinaldo Bellomo; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-08-16       Impact factor: 6.925

4.  Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?

Authors:  Bruno Van Herendael; Axel Jeurissen; Paul M Tulkens; Erika Vlieghe; Walter Verbrugghe; Philippe G Jorens; Margareta Ieven
Journal:  Ann Intensive Care       Date:  2012-07-02       Impact factor: 6.925

Review 5.  Does prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.

Authors:  Pranita D Tamma; Nirupama Putcha; Yong D Suh; Kyle J Van Arendonk; Michael L Rinke
Journal:  BMC Infect Dis       Date:  2011-06-22       Impact factor: 3.090

6.  Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.

Authors:  Ivan Chytra; Martin Stepan; Jan Benes; Petr Pelnar; Alexandra Zidkova; Tamara Bergerova; Richard Pradl; Eduard Kasal
Journal:  Crit Care       Date:  2012-06-28       Impact factor: 9.097

7.  Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia.

Authors:  Fanak Fahimi; Somayeh Ghafari; Hamidreza Jamaati; Shadi Baniasadi; Payam Tabarsi; Arvin Najafi; Arnavaz Akhzarmehr; Seyed Mohammad Reza Hashemian
Journal:  Indian J Crit Care Med       Date:  2012-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.